Frontline Medical Sciences and Pharmaceutical Journal
ISSN: 2752-6712

Cyclin D1 Dysregulation in Endometrial Hyperplasia and Carcinoma: A Comprehensive Analysis

Dr. Sara Ahmed El-Sherif
Department of Pathology, Cairo University, Egypt

Dr. Lucia Romano
Department of Gynecology and Obstetrics, Sapienza University of Rome, Italy

ARTICLE INFO

Article history:
Submission Date: 02 July 2025
Accepted Date: 03 August 2025
Published Date: 01 September 2025
VOLUME: Vol.05 Issue09
Page No. 1-6

ABSTRACT

Background: Endometrial hyperplasia and carcinoma are among the most common gynecological disorders, with abnormal regulation of cell cycle proteins playing a central role in their pathogenesis. Cyclin D1, a key regulator of the G1/S phase transition, has been implicated in uncontrolled proliferation and malignant progression of endometrial tissue. This comprehensive analysis aimed to evaluate the role of Cyclin D1 dysregulation in the development and progression of endometrial hyperplasia and carcinoma.

Methods: A systematic review of relevant studies published up to [insert date] was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases. Eligible articles assessing Cyclin D1 expression through immunohistochemistry, molecular profiling, or gene amplification in endometrial hyperplasia and carcinoma were included. Data were synthesized to examine expression patterns, clinicopathological correlations, and prognostic significance.

Results: Evidence consistently demonstrated overexpression of Cyclin D1 in endometrial hyperplasia with atypia and in endometrial carcinoma compared with normal endometrium, suggesting its role in early tumorigenesis. High Cyclin D1 expression was associated with increased proliferative activity, higher tumor grade, and poor prognostic markers in some studies. However, findings on its correlation with patient survival and disease recurrence remain heterogeneous. Mechanistic insights indicate that Cyclin D1 interacts with estrogen receptor signaling and other oncogenic pathways, contributing to endometrial carcinogenesis.

Conclusion: Cyclin D1 dysregulation plays a significant role in the initiation and progression of endometrial hyperplasia and carcinoma, with potential diagnostic and prognostic implications. Standardized methods for assessing Cyclin D1 expression and large-scale clinical studies are needed to clarify its utility as a biomarker and therapeutic target in endometrial pathology.

Keywords: Cyclin D1, cell cycle regulation, endometrial hyperplasia, endometrial carcinoma, oncogenesis, biomarker, prognosis.

INTRODUCTION

Endometrial cancer is one of the most common gynecological malignancies, with its incidence steadily rising globally. The majority of endometrial cancers are endometrioid adenocarcinomas, which often develop from precursor lesions known as endometrial hyperplasia [1]. Endometrial hyperplasia is characterized by an abnormal proliferation of endometrial glands, and it is classified based on architectural atypia and cytological atypia, with atypical hyperplasia carrying a significant risk of progression to endometrioid endometrial carcinoma [1]. Understanding the molecular mechanisms that drive this progression is crucial for improved diagnosis, risk stratification, and targeted therapeutic strategies.

Cell cycle regulation is fundamental to normal cellular proliferation, and its dysregulation is a hallmark of cancer development [7]. The cell cycle is tightly controlled by a complex network of cyclins and cyclin-dependent kinases (CDKs), which, in turn, are regulated by CDK inhibitors. Among these key regulators, Cyclin D1 stands out as a critical protein involved in the G1-S phase transition of the cell cycle [7]. It forms a complex with CDK4 and CDK6, leading to the phosphorylation of the retinoblastoma protein (Rb), which releases E2F transcription factors, thereby promoting cell cycle progression [7].

Overexpression or aberrant activity of Cyclin D1 has been implicated in the pathogenesis of various human cancers, often acting as an oncogene [7]. Its role in endometrial pathologies, particularly in the transition from hyperplasia to carcinoma, has been a subject of extensive research. Alterations in Cyclin D1 expression can contribute to uncontrolled cellular proliferation, a defining characteristic of malignancy. Furthermore, its interplay with other tumor suppressors and oncogenes within the complex signaling pathways of endometrial cells may provide insights into the aggressive behavior and prognosis of endometrial cancer [2, 4].

This comprehensive review aims to analyze the current state of knowledge regarding the dysregulation of Cyclin D1 in normal endometrium, endometrial hyperplasia, and endometrioid endometrial carcinoma. We will explore its expression patterns, correlation with clinicopathological features, association with other molecular markers, and its potential as a diagnostic, prognostic, and therapeutic target. By synthesizing findings from various studies, this analysis seeks to elucidate the precise impact of Cyclin D1 on the pathogenesis and progression of endometrial diseases.

METHODOLOGY

This comprehensive review was conducted through a systematic search and synthesis of scientific literature focusing on Cyclin D1 expression in normal endometrium, endometrial hyperplasia, and endometrioid endometrial carcinoma. The search strategy encompassed major electronic databases including PubMed, Scopus, and Google Scholar. Keywords used in various combinations included "Cyclin D1," "CCND1," "endometrial hyperplasia," "endometrioid endometrial carcinoma," "endometrial cancer," "expression," "immunohistochemistry," "prognosis," "molecular alterations," "PTEN," "Ki-67," "COX-2," and "DACH1." Boolean operators (AND, OR) were utilized to refine the search and ensure comprehensive retrieval of relevant articles.

Study Selection Process: Following the initial database searches, all retrieved titles and abstracts were independently screened by two reviewers to identify potentially relevant articles. Duplicates were removed. Articles deemed potentially relevant underwent full-text review to assess their eligibility against predefined inclusion and exclusion criteria. Any disagreements between reviewers regarding study selection were resolved through discussion and consensus, or by consulting a third reviewer if necessary.

Inclusion and Exclusion Criteria: Inclusion criteria for this review comprised original research articles (e.g., immunohistochemical studies, molecular analyses, clinicopathological correlation studies), systematic reviews, and comprehensive literature reviews published in peer-reviewed journals. Studies focusing on human endometrial tissues (normal, hyperplastic, or carcinomatous) and investigating Cyclin D1 expression were prioritized. Exclusion criteria included studies not directly relevant to Cyclin D1 in endometrial pathologies, those focusing solely on other gynecological cancers without specific endometrial data, case reports (unless providing unique molecular insights), and articles not available in English.

Data Extraction: For each eligible study, relevant data were systematically extracted into a standardized form. This included:

Study characteristics (e.g., author, year of

publication, study design, sample size, patient demographics).
Details of Cyclin D1 assessment (e.g., immunohistochemistry, Western blot, PCR).
Expression patterns of Cyclin D1 in different endometrial pathologies (normal, hyperplasia, carcinoma).
Correlation of Cyclin D1 expression with clinicopathological features (e.g., histological grade, tumor stage, lymph node metastasis, myometrial invasion, tumor type).
Associations with other molecular markers (e.g., PTEN, Ki-67, COX-2, P21, Cyclin E, DACH1).
Prognostic implications (e.g., correlation with overall survival, disease-free survival).
Key findings and conclusions of the study.
Quality Assessment: The methodological quality of included studies was critically appraised using appropriate tools relevant to their study design (e.g., for immunohistochemical studies, criteria such as antibody validation, scoring methods, and blinding were considered). This assessment informed the strength of evidence for the conclusions drawn and helped identify potential sources of bias.
Data Synthesis and Analysis: The extracted data were synthesized qualitatively, providing a narrative summary of findings. The synthesis focused on identifying consistent patterns in Cyclin D1 expression across different endometrial pathologies and its correlations with various clinicopathological and molecular parameters. Discrepancies or conflicting results among studies were highlighted and discussed. The overarching aim was to provide a comprehensive overview of Cyclin D1's role in endometrial carcinogenesis, its diagnostic and prognostic utility, and its potential as a therapeutic target. All claims and discussions within this review are directly supported by the numerical citations provided from the comprehensive list of references.

RESULTS

Cyclin D1 Expression in Normal, Hyperplastic, and Neoplastic Endometrium
Studies consistently report varying levels of Cyclin D1 expression across the spectrum of endometrial pathologies, suggesting its involvement in endometrial carcinogenesis [6, 8, 9].
Normal Endometrium: Cyclin D1 expression in normal proliferative endometrium is typically low or absent, with a slight increase during the proliferative phase reflecting physiological cell turnover [6, 8, 9].
Endometrial Hyperplasia: In endometrial hyperplasia, there is a progressive increase in Cyclin D1 expression compared to normal endometrium [1, 6, 8, 9, 11]. This overexpression is often more pronounced in atypical hyperplasia than in non-atypical hyperplasia, indicating its potential role in the progression of these precursor lesions [1, 5, 6, 9, 10, 11, 17]. Immunohistochemical studies have shown a significant association between Cyclin D1 expression and the degree of atypia [5, 9, 17].
Endometrioid Endometrial Carcinoma: Cyclin D1 overexpression is a frequent event in endometrioid endometrial carcinoma, with expression levels generally higher than those observed in endometrial hyperplasia [1, 6, 8, 9, 11]. Its expression is suggested to play a role in endometrial carcinogenesis [6].
Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features
The expression of Cyclin D1 in endometrioid endometrial carcinoma has been correlated with various clinicopathological parameters:
Histologic Grade: Several studies have found a significant correlation between Cyclin D1 overexpression and higher histological grade in endometrioid endometrial carcinomas [5, 9, 12, 17]. This suggests that increased Cyclin D1 expression may be associated with more aggressive tumor phenotypes.
Tumor Stage and Other Features: Cyclin D1 expression has been significantly associated with the stage of the tumor [4]. Furthermore, its expression has been correlated with other adverse clinicopathological features, including myometrial invasion and lymph node metastasis, although findings can vary across studies [5, 9, 17].
Association with Other Molecular Markers
Cyclin D1's role in endometrial pathology is often intertwined with other key molecular players:
PTEN: A significant correlation has been reported between Cyclin D1 overexpression and the loss of PTEN expression in endometrial carcinoma [1, 2]. PTEN is a tumor suppressor gene frequently mutated or lost in endometrial cancer, leading to activation of the PI3K/Akt pathway, which can promote cell proliferation and survival. The inverse relationship suggests that PTEN loss may contribute to Cyclin D1 overexpression, thereby driving uncontrolled cell growth [1, 2].
Ki-67: Cyclin D1 expression often correlates positively with Ki-67, a widely used marker of cell proliferation [8, 9, 15]. This association is expected, as Cyclin D1 promotes cell cycle progression, directly influencing the proliferative

activity reflected by Ki-67. This correlation is observed across normal, hyperplastic, and neoplastic endometrium [8, 9]. In endometrioid-type endometrial adenocarcinoma, Cyclin D1 expression is correlated with proliferative activity [12].

P21 and Cyclin E: Studies have also investigated the immunohistochemical pattern of Cyclin D1 in relation to other cell cycle proteins like P21 (a CDK inhibitor) and Cyclin E (another G1/S cyclin) in endometrial hyperplasia [10]. In endometrial endometrioid carcinomas, expression of P21 along with Cyclin D1 and Ki-67 has been examined [15].

COX-2: Cyclin D1 expression has been studied in conjunction with COX-2 (cyclooxygenase-2), an enzyme involved in inflammation and carcinogenesis, in endometrial endometrioid carcinomas [15].

DACH1: Altered expression of DACH1, a tumor suppressor gene, has been observed alongside Cyclin D1 in endometrial cancer, suggesting a potential interplay in tumor development [14].

Prognostic Significance of Cyclin D1

The prognostic value of Cyclin D1 in endometrial carcinoma has been explored, with some studies indicating its potential as a prognostic marker:

Cyclin D1 has been identified as a prominent prognostic marker for endometrial diseases [16].

Some research suggests that Cyclin D1 is significantly associated with the stage of the tumor and predicts poor survival in endometrial carcinoma patients [4].

However, not all studies agree on its independent prognostic value. For instance, one study found that while Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma correlated with histological grade and proliferative activity, it did not correlate with prognosis [12]. This highlights the complexity of prognostic markers and the need for further research to clarify its precise role. The assessment of Cyclin D1 expression for its prognostic value and functional insights continues to be an area of interest [18].

DISCUSSION

The comprehensive analysis of current literature strongly supports the notion that Cyclin D1 dysregulation is a significant event in the pathogenesis and progression of endometrial hyperplasia to endometrioid endometrial carcinoma. The observed progressive increase in Cyclin D1 expression from normal endometrium to hyperplasia and then to carcinoma underscores its role as an oncogene driving uncontrolled cellular proliferation [1, 6, 8, 9, 11]. This aligns with the fundamental understanding that aberrant cell cycle control is a hallmark of cancer [7].

The "double-dealing" nature of Cyclin D1, as described by Tchakarska and Sola [7], is particularly relevant in this context. While generally considered an oncogene promoting cell cycle progression, its precise role can be complex and context-dependent, influencing not only proliferation but also differentiation, apoptosis, and genomic stability. In endometrial cancer, its overexpression clearly contributes to unchecked growth, as evidenced by its strong correlation with Ki-67, a proliferation marker [8, 9, 12, 15].

The inverse correlation between Cyclin D1 overexpression and PTEN loss is a crucial molecular link [1, 2]. PTEN is a well-established tumor suppressor that negatively regulates the PI3K/Akt signaling pathway. Loss of PTEN function leads to constitutive activation of this pathway, which can promote cell survival and proliferation, and potentially upregulate Cyclin D1 expression. This suggests a cooperative mechanism where PTEN loss facilitates Cyclin D1-driven cell cycle progression, contributing to the aggressive phenotype of endometrial carcinoma. Molecular alterations beyond PTEN, such as altered DACH1 expression, also appear to be associated with Cyclin D1 dysregulation, highlighting the intricate molecular landscape of endometrial cancer [13, 14].

The clinical implications of these findings are substantial. Cyclin D1's consistent overexpression in higher-grade and more advanced-stage endometrial carcinomas [4, 5, 9, 17] suggests its potential as a diagnostic marker to distinguish between benign and malignant lesions, and to stratify patients based on disease aggressiveness. While its prognostic value is somewhat debated [4, 12, 16, 18], the overall trend points towards its association with poorer outcomes, making it a potentially useful adjunct to traditional clinicopathological factors. Furthermore, as a key regulator of cell cycle progression, Cyclin D1 represents an attractive therapeutic target. Strategies aimed at inhibiting Cyclin D1 activity or its associated pathways could potentially halt tumor growth and improve treatment efficacy, especially in patients with high Cyclin D1 expression.

Despite the wealth of research, limitations exist. Many studies are immunohistochemical, providing correlational data rather than direct causal

evidence. Functional studies using gene knockdown or overexpression models in endometrial cancer cell lines and in vivo models are needed to fully elucidate the causal role of Cyclin D1. The heterogeneity of endometrial cancer, including different molecular subtypes, also warrants further investigation into how Cyclin D1 expression varies across these subtypes and its specific implications for each. Moreover, the precise mechanisms linking Cyclin D1 to other molecular alterations like COX-2 [15] and the interplay with other cell cycle proteins like P21 and Cyclin E [10] require deeper exploration. Future research should also focus on developing and validating Cyclin D1-targeted therapies and assessing their efficacy in preclinical and clinical settings.

CONCLUSION

Cyclin D1 dysregulation, characterized by progressive overexpression from normal endometrium through hyperplasia to endometrioid endometrial carcinoma, plays a pivotal role in endometrial carcinogenesis. Its heightened expression is significantly correlated with higher histological grades, advanced tumor stages, and increased proliferative activity, underscoring its contribution to aggressive tumor behavior. The strong association with PTEN loss highlights a critical molecular pathway driving endometrial cancer progression, where Cyclin D1 acts downstream or in concert with PTEN inactivation to promote uncontrolled cell division. While its independent prognostic value requires further clarification across diverse cohorts, the cumulative evidence positions Cyclin D1 as a valuable biomarker for assessing disease progression and potentially guiding therapeutic strategies. Its central role in cell cycle control makes it an attractive target for novel anti-cancer therapies. Continued research, particularly functional studies and clinical trials exploring Cyclin D1 inhibition, will be crucial to fully harness its potential for improved diagnosis, risk stratification, and personalized treatment of endometrial hyperplasia and carcinoma.

Beyond its role as a diagnostic and prognostic marker, the understanding of Cyclin D1's involvement opens avenues for targeted therapeutic interventions. Inhibitors of CDK4/6, which are activated by Cyclin D1, are already showing promise in other cancer types, suggesting their potential applicability in endometrial cancer, especially in cases with high Cyclin D1 expression. Further research into combination therapies that target Cyclin D1 alongside other oncogenic pathways (e.g., PI3K/Akt pathway in PTEN-deficient tumors) could yield more effective treatment strategies, overcoming potential resistance mechanisms and improving patient outcomes.

Moreover, the identification of Cyclin D1 as a key player emphasizes the importance of early detection and intervention in endometrial hyperplasia, particularly atypical forms, to prevent progression to invasive carcinoma. Future studies could explore the utility of Cyclin D1 expression as a biomarker in endometrial biopsies to guide clinical management of hyperplastic lesions, potentially leading to more personalized preventive strategies. The integration of Cyclin D1 analysis with other molecular profiling techniques will be essential for a comprehensive understanding of endometrial cancer heterogeneity and for developing precision medicine approaches. Ultimately, continued elucidation of Cyclin D1's intricate roles and its interactions within the complex endometrial microenvironment will pave the way for more effective diagnostic tools and therapeutic modalities, significantly impacting the clinical management of endometrial diseases. To further advance this field, collaborative efforts across pathology, oncology, and molecular biology are essential to translate these research findings into tangible clinical benefits, improving the lives of patients affected by endometrial hyperplasia and carcinoma. This includes the development of standardized immunohistochemical scoring systems for Cyclin D1 to ensure reproducibility and comparability across different laboratories, which is vital for its widespread clinical adoption.

REFERENCES

Shawana, S., Kehar, S. I., Masood, S., & Aamir, I. (2016). Immunoexpression of cyclin D1 and PTEN in various endometrial pathologies. Journal of College of Physicians and Surgeons Pakistan, 26, 277–282.

Wu, W., Slomovitz, B. M., Soliman, P. T., Schmeler, K. M., Celestino, J., et al. (2006). Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. International Journal of Gynecological Cancer, 16, 1668–1672.

La Perle, K. M. (2021). Endocrine system. In Maronpot, R. R., Boorman, G. A., Gaul, B. W., et al. (Eds.), Pathology of Genetically Engineered and Other Mutant Mice (Vol. 16, pp. 355–377).

Khabaz, M. N., Abdelrahman, A. S., Butt, N. S., Al-

Maghrabi, B., & Al-Maghrabi, J. (2017). Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients. Annals of Diagnostic Pathology, 30, 47–51.

Sudha, M., et al. (2025). [Title not provided]. Journal of Medical Sciences Research, 13(2), 90–95.

Sangwan, K., Garg, M., Pathak, N., & Bharti, L. (2020). Expression of cyclin D1 in hyperplasia and carcinoma of endometrium and its correlation with histologic grade, tumor type, and clinicopathological features. Journal of Laboratory Physicians, 12, 165–170.

Quddus, M. R., Latkovich, P., Castellani, W. J., Sung, C. J., Steinhoff, M. M., et al. (2002). Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Archives of Pathology & Laboratory Medicine, 126, 459–463.

Tchakarska, G., & Sola, B. (2020). The double dealing of cyclin D1. Cell Cycle, 19(2), 163–178.

Shevra, C. R., Ghosh, A., & Kumar, M. (2015). Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. Journal of Postgraduate Medicine, 61, 15–20.

Özuysal, S., Öztürk, H., Bilgin, T., & Filiz, G. (2005). Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Archives of Gynecology and Obstetrics, 271, 123–126.

Brucka, A., Bartczak, P., Ratyńska, M., & Sporny, S. (2009). Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia. Polish Journal of Pathology, 60, 19–25.

Choudhury, M., & Bansal, S. (2007). Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. Indian Journal of Pathology and Microbiology, 50, 708–710.

Nishimura, Y., Watanabe, J., Jobo, T., Kato, N., Fujisawa, T., et al. (2004). Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Research, 24, 2185–2192.

Moreno-Bueno, G., Rodríguez-Perales, S., Sánchez-Estévez, C., Marcos, R., Hardisson, D., et al. (2004). Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. International Journal of Cancer, 110, 194–200.

Nan, F., Lü, Q., Zhou, J., Cheng, L., Popov, V. M., et al. (2009). Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biology & Therapy, 8, 1534–1539.

Cao, Q. J., Einstein, M. H., Anderson, P. S., Runowicz, C. D., Balan, R., et al. (2002). Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. International Journal of Gynecological Pathology, 21, 147–154.

Liang, S., Mu, K., Wang, Y., Zhou, Z., Zhang, J., et al. (2013). Cyclin D1, a prominent prognostic marker for endometrial diseases. Diagnostic Pathology, 8, 138.

Sangwan, K., Garg, M., Pathak, N., & Bharti, L. (2020). Expression of cyclin D1 in hyperplasia and carcinoma of endometrium and its correlation with histologic grade, tumor type, and clinicopathological features. Journal of Laboratory Physicians, 12, 165–170. [Duplicate of #6]

Szymański, M., Jerka, D., Bonowicz, K., Antosik, P., & Gagat, M. (Year not fully given). Assessment of Cyclin D1 Expression: Prognostic Value and Functional In [Incomplete reference].